文献速递妇科

错配修复状态能否加入子宫内膜样子宫内膜癌的前哨淋巴结定位算法?

Can mismatch repair status be added to sentinel lymph node mapping algorithm in endometrioid endometrial cancer?
PubMed 文献 · Gynecol Oncol · 2022-12-27

研究纳入2013年1月至2021年12月期间接受前哨淋巴结定位±系统性淋巴结清扫的332例子宫内膜样子宫内膜癌患者,评估错配修复状态与淋巴结转移风险的关系及其能否整合入现有前哨淋巴结算法。错配修复缺陷占20.8%,为淋巴结转移的独立危险因素(OR 2.76,95%CI 1.36-5.62),在非双侧前哨淋巴结检出病例中,纳入错配修复状态可使53.7%(43/80)的病例免于系统性淋巴结清扫。

要点

  • 错配修复缺陷占20.8%,与3级(p=0.018)及脉管间隙浸润(p=0.032)相关。
  • 错配修复缺陷是淋巴结转移的独立危险因素(OR 2.76,95%CI 1.36-5.62)。
  • 非双侧前哨淋巴结检出且错配修复缺陷者,或可免于系统性淋巴结清扫。

核心结论

  • 在子宫内膜样子宫内膜癌中,错配修复状态与淋巴结转移独立相关。
  • 错配修复状态可能有助于筛选在前哨淋巴结未检出时可否免于系统性淋巴结清扫的患者。

研究设计与样本

  • 纳入332例于2013年1月至2021年12月接受前哨淋巴结定位±系统性淋巴结清扫的子宫内膜样子宫内膜癌患者。
  • 采用免疫组织化学检测MLH1、MSH2、MSH6、PMS2蛋白表达,至少一种蛋白未表达定义为错配修复缺陷。

主要发现

  • 错配修复缺陷占20.8%,与3级(p=0.018)及脉管间隙浸润(p=0.032)相关。
  • 错配修复缺陷是淋巴结转移的独立危险因素(OR 2.76,95%CI 1.36-5.62)。
  • 错配修复缺陷组淋巴结转移率为21.7%(15/69),错配修复完整组为9.5%(25/263)(p=0.005)。
  • 前哨淋巴结总体检出率为91.9%,双侧检出率为75.9%。
  • 80例(24%)非双侧前哨淋巴结检出病例中,66.2%为低级别肿瘤(G1/G2)且肌层浸润<50%。

关键数值与推荐

  • 错配修复缺陷定义为至少一种错配修复蛋白(MLH1、MSH2、MSH6、PMS2)免疫组织化学未表达。

临床怎么用

  • 作者认为,错配修复状态可能有助于在前哨淋巴结未检出时筛选可免于系统性淋巴结清扫的患者。
  • 考虑错配修复状态为淋巴结转移的独立预后因素,在非双侧前哨淋巴结检出病例中,53.7%(43/80)可免于系统性淋巴结清扫,占全部子宫内膜样肿瘤的13%(43/332)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the relation between mismatch repair (MMR) status and the risk of lymph node metastasis in endometrial cancer, and whether this additional data can be incorporated to current SLN (sentinel lymph node) algorithm. METHODS: We included a series of 332 women that underwent SLN mapping ± systematic lymphadenectomy from January 2013 to December 2021. Protein expressions of MLH1, MSH2, MSH6, PMS2 were examined by immuno-histochemistry and considered MMRd (deficient) when at least one protein was not expressed. RESULTS: MMRd was noted in 20.8% of cases and correlated to grade 3 (p = 0.018) and presence of lymphovascular space invasion (p = 0.032). Moreover, MMRd was an independent risk factor for lymph node metastasis (OR 2.76, 95% CI 1.36-5.62). Notably, 21.7% (15/69) cases with MMRd had lymph node metastasis compared to 9.5% (25/263) of cases with MMRp (proficient) (p = 0.005). The overall and bilateral SLN detection rates were 91.9% and 75.9%, respectively. Of the 80 (24%) cases of non-bilateral SLN detection, 66.2% had low-grade tumors (G1/G2) and myometrial invasion <50%. Considering MMR status an independent prognostic factor for lymph node metastasis, a systematic lymphadenectomy (side specific or bilateral) would forgo in 53.7% (43/80) of cases with non-bilateral detection, representing 13% (43/332) of all endometroid tumors. CONCLUSION: MMR status was independently related to lymph node metastasis in endometrioid EC. Moreover, MMR status may help to select patients that can forgo systematic lymphadenectomy in case of undetected SLN.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Diniz TP, Menezes JN, Goncalves BT, et al. Can mismatch repair status be added to sentinel lymph node mapping algorithm in endometrioid endometrial cancer? Gynecol Oncol. 2022. PMID: 36580755. doi:10.1016/j.ygyno.2022.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。